Need to keep on prime of the science and politics driving biotech in the present day? Enroll to get our biotech publication in your inbox.
Oh hello. Right now, we speak about Eli Lilly’s plan to take a position $27 billion into new manufacturing websites stateside, study a brand new wave of biotech VCs, and extra.
The necessity-to-know this morning
- STAT’s Adam Feuerstein, in his weekly Biotech Scorecard publication, writes a couple of counterintuitive, however ingenious, resolution to the “zombie” drawback amongst biotechs: Purchase them and shut them down.
- Argenx, Europe’s different prime biotech, reported fourth-quarter and 2024 earnings.
Biotech’s new era of enterprise capitalists
A brand new wave of biotech enterprise capital corporations, led by youthful buyers, is reshaping the trade with recent methods and a concentrate on synthetic intelligence, longevity, and computational biology. Whereas conventional VC corporations keep dominant, these newcomers — many of their 30s and 40s — are securing main funding and backing scientific founders.
STAT’s Allison DeAngelis is out this morning with a rundown of a number of the buzziest new VCs, together with Dimension Capital’s Adam Goulburn, KdT Ventures’ Cain McClary, and Atria Ventures’ Chris Leiter.
“I feel the founders are on the lookout for new blood, and the capital markets … are on the lookout for new blood,” Dar mentioned.
Lilly invests $27 billion in U.S. drug manufacturing
Eli Lilly introduced yesterday that it’ll make investments $27 billion into 4 new drug manufacturing websites within the U.S., aligning with the Trump administration’s push to deliver pharmaceutical manufacturing stateside. The websites may wish as many as 10,000 development jobs and three,000 technical jobs. Lilly additionally touted its earlier $23 billion funding in home manufacturing over the previous 4 years, which incorporates new websites in North Carolina, Indiana, and Wisconsin.
Throughout a press convention in Washington, CEO Dave Ricks emphasised the corporate’s nationwide satisfaction, underscoring how the corporate was based by a U.S. Military veteran. A number of Trump administration officers attended the occasion as properly.
“I’m honored to be right here in the present day as a result of Eli Lilly is doing precisely what the President hoped would occur, which is having tens of billions of {dollars} of funding in America,” Secretary of Commerce Howard Lutnick mentioned.
FDA cancels flu vaccine advisory committee assembly
The FDA has abruptly canceled a key vaccine advisory committee assembly scheduled for March 13 — leaving vaccine makers with out vital steerage on flu pressure choice for the upcoming season. Commitee member Paul Offit confirmed the cancellation, noting that have been no plans to reschedule it.
“It’s an vital assembly,” Offit mentioned. “Vaccine makers look to this assembly to find out which strains to incorporate on this 12 months’s vaccine.”
The choice follows a sample of advisory assembly cancellations beneath the Trump administration. In the meantime, the WHO is continuing with flu pressure suggestions, with U.S. officers attending just about.
Reforming drug approval with progressive trials
The FDA is sluggish, deliberate, and reasonably risk-averse when it considers medicine for approval, argue Michael Stebbins, a geneticist and former White Home biotechnology advsier, and Eric Perakslis, a former FDA chief data officer. On the similar time, remedies substantiated by shaky information typically in the end command sky-high costs.
A progressive approval mannequin with a tiered system may work higher, the pair opine in a brand new First Opinion essay.
This method would incentivize drugmakers as real-world proof accumulates, they are saying. By integrating medical trial alternatives into routine care by means of digital well being information, extra sufferers may entry experimental remedies earlier — and data-sharing necessities would guarantee the continual monitoring of security and efficacy.
NIH oblique value cap sparks funding debate
The Trump administration’s proposal to cap NIH oblique prices at 15% has drawn criticism from universities, researchers, and policymakers, who argue it undermines analysis infrastructure. Whereas personal foundations pay decrease overhead, they are saying, universities settle for these charges solely as a result of federal funding covers most of their analysis bills. Personal basis funding serves as a helpful add-on.
The cap may power establishments to reclassify bills, reduce workers, and cut back analysis capabilities, in the end destabilizing tutorial science. Specialists acknowledge inefficiencies within the present system, however argue that drastically reducing oblique value charges with out another funding mannequin may hinder scientific discovery and innovation.
Extra reads
- Wearable defibrillator maker Kestra Medical plots $150M IPO, FierceBiotech